Dienogest alone or dienogest combined with estrogens in the treatment of ovarian endometriomas, that is the question. A retrospective cohort study.

Authors:
  • AAAnna Chiara Aru
    Anna Chiara Aru
  • JLJacopo Lenzi
    Jacopo Lenzi

Abstract
Purposeto compare the effects of Dienogest 2 mg (D) alone or combined with estrogens (D + ethinylestradiol 0.03 mg, D + EE; D + estradiol valerate 1–3 mg, D + EV) in terms of symptoms and endometriotic lesions variations.MethodsThis retrospective study included symptomatic patients in reproductive age with ultrasound diagnosis of ovarian endometriomas. Medical therapy for at least 12 months with D, D + EE or D + EV was required. Women were evaluated at baseline visit (V1) and after 6 (V2) and 12 months (V3) of therapy.Results297 patients were enrolled (156 in the D group, 58 in the D + EE group, 83 in the D + EV group). There were no differences between groups in terms of lesions mean diameter variation. No variations were detected in terms of lesions reduction when comparing the two estroprogestins, cyclic versus continuous estroprogestin regimens, D alone versus D + EE/D + EV administered continuously. When comparing D and D + EE/D + EV groups, a significant decrease of dysmenorrhea was detected in the D group than in D + EE/D + EV group. Conversely, the reduction of dysuria was more significative in the D + EE/D + EV groups rather than in the D group. Regarding tolerability, treatment associated side effects were reported by 16.2% patients. The most frequent one was uterine bleeding/spotting, significantly higher in the D + EV group.ConclusionDienogest alone or associated with estrogens (EE/EV) seems to be equally effective in reducing endometriotic lesions mean diameter. The reduction of dysmenorrhea was more significative when D was administered alone, while dysuria seems to improve more when D is associated with estrogens.

This publication has 26 references indexed in Scilit: